Feasibility of Long-Term Patient Self-Reporting of Toxicities From Home via the Internet During  Routine Chemotherapy by Judson, Timothy J. et al.
Feasibility of Long-Term Patient Self-Reporting of
Toxicities From Home via the Internet During
Routine Chemotherapy
Timothy J. Judson, Antonia V. Bennett, Lauren J. Rogak, Laura Sit, Allison Barz, Mark G. Kris,
Clifford A. Hudis, Howard I. Scher, Paul Sabattini, Deborah Schrag, and Ethan Basch
Timothy J. Judson and Ethan Basch,
Weill Cornell Medical College; Antonia
V. Bennett, Lauren J. Rogak, Laura Sit,
Allison Barz, Mark G. Kris, Clifford A.
Hudis, Howard I. Scher, Paul Sabattini,
and Ethan Basch, Memorial Sloan-
Kettering Cancer Center, New York,
NY; Deborah Schrag, Dana-Farber
Cancer Institute, Boston, MA; and
Ethan Basch, University of North Caro-
lina, Chapel Hill, NC.
Published online ahead of print at
www.jco.org on June 3, 2013.
Supported by National Cancer Institute
Grant No. 5K07CA124851.
Authors’ disclosures of potential con-
flicts of interest and author contribu-
tions are found at the end of this
article.
Corresponding author: Ethan Basch,
MD, MSc, Cancer Outcomes Research
Program, University of North Carolina,
170 Manning Dr CB# 7305, Physicians’
Office Bldg, Suite 3185, Chapel Hill, NC
27599-7305; e-mail: ebasch@med.unc
.edu.




A B S T R A C T
Purpose
Patient-reported outcomes are increasingly used in routine outpatient cancer care to guide clinical
decisions and enhance communication. Prior evidence suggests good patient compliance with
reporting at scheduled clinic visits, but there is limited evidence about compliance with long-term
longitudinal reporting between visits.
Patients and Methods
Patients receiving chemotherapy for lung, gynecologic, genitourinary, or breast cancer at a tertiary
cancer center, with access to a home computer and prior e-mail experience, were asked to
self-report seven symptomatic toxicities via the Web between visits. E-mail reminders were sent
to participants weekly; patient-reported high-grade toxicities triggered e-mail alerts to nurses;
printed reports were provided to oncologists at visits. A priori threshold criteria were set to
determine if this data collection approach merited further development based on monthly ( 75%
participants reporting at least once per month on average) and weekly compliance rates (60% at
least once per week).
Results
Between September 2006 and November 2010, 286 patients were enrolled (64% were women;
88% were white; median age, 58 years). Mean follow-up was 34 weeks (range, 2 to 214). On
average, monthly compliance was 83%, and weekly compliance was 62%, without attrition until
the month before death. Greater compliance was associated with older age and higher education
but not with performance status. Compliance was greatest during the initial 12 weeks. Symptom-
atic illness and technical problems were rarely barriers to compliance.
Conclusion
Monthly compliance with home Web reporting was high, but weekly compliance was lower,
warranting strategies to enhance compliance in routine care settings.
J Clin Oncol 31:2580-2585. © 2013 by American Society of Clinical Oncology
INTRODUCTION
The use of patient-reported outcomes (PROs) in
routine clinical practice has received recent interest
by health care providers for its potential to improve
symptom management, communication, and effi-
ciency of clinical operations.1-6 Medical, surgical,
and radiation oncology practices are integrating
PROs into their clinical workflow, and several soft-
ware vendors of electronic medical records are offer-
ing PRO assessment modules as optional packages.1
This movement follows the uptake of PRO use in
cancer clinical trials in both the regulatory and co-
operative group settings, in which PROs have be-
come a mainstay of study design to capture the
patient perspective.7-11
Recent interest in PROs in health care has
evolved amid a broader milieu of patient-
centeredness in the United States12,13 and is based on
a growing body of evidence demonstrating that
PROs improve quality of care and patient-provider
communication.2,14-16 Moreover, PROs can flag
symptoms that providers systematically miss or
downgrade, such as nausea, neuropathy, fatigue,
dyspnea, and anorexia; failure to note these symp-
toms may result in subsequent health problems that
otherwise could have been prevented.17-20
Previous work has demonstrated that in
industry-sponsored clinical trials, remote electronic
self-reporting (ie, home reporting) is feasible and
can have high levels of compliance.21-23 However,
these trials were conducted in carefully selected and
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motivated patient populations with good baseline performance status,
with close follow-up by data managers within a robust infrastructure.
In contrast, routine-care patients include all comers—that is, patients
of variable performance status who may have little or no interest in
self-reporting. Moreover, outside the context of clinical trials, research
staff are not in place to engage patients to self-report between visits.
The feasibility of patient self-reporting during routine chemo-
therapy care at clinic visits via waiting room tablet computers has also
been reported, with mean compliance rates ranging from 75% to 85%,
high patient satisfaction, and good usability of systems even among
the non–Web avid (ie, non–Internet familiar), the elderly, or frail
individuals.6,24,25 However, this work does not provide evidence about
the feasibility of home reporting between visits. Between-visit report-
ing is of particular interest because of the ability to monitor patients
when they are away from the clinic but experiencing symptoms that
merit changes in management.3,26-31
Therefore, we sought to examine long-term patient compli-
ance rates with self-reporting of seven common symptomatic tox-
icities associated with chemotherapy and to identify variables
associated with greater or lesser compliance across multiple cancer
types. Compliance rates for different frequencies of self-reporting
were of interest (eg, at least once per month, per 2 weeks, and per
week) to inform future implementation strategies, because these
frequencies of reporting may be appropriate in different treatment
contexts where more or less common symptom information is
meaningful for decision making.
PATIENTS AND METHODS
Study Design and Patient Population
A preplanned feasibility study of self-reporting compliance was embed-
ded within a larger, randomized controlled trial assessing the potential clinical
benefits of PRO assessment in routine cancer care.32 The feasibility study
entailed one of three trial arms, in which patients were assigned to regularly
self-report a set of symptomatic toxicities from home between clinic visits and
from clinic waiting areas on dates of visits via a Web survey composed of
previously established PRO measures.6,25,33
Patients being treated at Memorial Sloan-Kettering Cancer Center
(MSKCC) lung, gynecologic, breast, and genitourinary outpatient clinics were
identified if they were starting a new chemotherapy regimen and not currently
in a clinical treatment trial. To be eligible for the feasibility study, patients had
to indicate Web avidity (ie, Internet familiarity) in a baseline questionnaire
defined as access to a computer and the Internet at home with prior e-mail
experience and be able to read and understand English.
Eligible patients were approached in clinic waiting areas and invited to
participate in this institutional review board–approved study. To be enrolled
onto the study and analyzed, patients were required to complete informed
consent and a baseline symptom survey.
Patients were discontinued from the study when they ceased systemic
anticancer therapy at MSKCC or voluntarily disenrolled. Therefore, all pa-
tients were considered to be receiving active treatment during participation.
Symptom Tracking
Enrolled patients underwent a 15-minute training session via a tablet
computer for a Web-based PRO software system called STAR (Symptom
Tracking and Reporting), which has been described previously.33 Training
included instructions on how to log into STAR and enter information about
symptomatic toxicities. STAR was only available in English at the time of this
study. Participants were told that although the STAR system would generate
reports for clinicians to review at subsequent visits, and it would trigger
automated e-mails to clinical staff for concerning or worsening symptoms, this
information might not necessarily be reviewed in real time. Therefore, they
should still contact clinical staff by telephone about concerning symptoms.
This stipulation was requested by the institutional review board.
Patients were asked to self-report from home during weeks they did not
have a clinic visit and were sent automated e-mails reminding them of the
availability of the online questionnaire and providing a link to it. However,
they could log in whenever and however often they wished, with no specific
requirement for timing of reporting. During clinic visits, patients were asked to
self-report using a clinic-based tablet computer or kiosk in waiting areas.
Patients were offered no financial incentive to self-report.
Each time a patient logged into the STAR Web site, he or she was
prompted to respond to seven plain-language questions about symptomatic
toxicities corresponding to items in the National Cancer Institute Common
Terminology Criteria for Adverse Events,34 including: pain, fatigue, nausea,
vomiting, constipation, diarrhea, and appetite loss.19 Patients were asked ad-
ditional questions to assess health state (via the EuroQoL EQ-5D) and patient-
reported performance status.25,35,36 Subsequently, at each clinic visit, a STAR
report was printed for providers showing patient responses for review by the
nurse and/or medical oncologist as part of standard care. In addition, real-time
automatic e-mails were triggered to nurses in the event of patients reporting
any grade 3 or 4 toxicities or in the event of symptoms worsening by  two
grade points since the prior visit.
Patients were eligible to continue using the STAR system until their
off-study date, which was defined as either the date of final chemotherapy
treatment at MSKCC, the date of voluntary withdrawal from the study, or the
date of overall trial closure. Baseline patient demographics, including age, sex,
highest level of education completed, and race/ethnicity, were reported by the
patient at time of enrollment. Stage of disease and Eastern Cooperative Oncol-
ogy Group (ECOG) performance status37 were abstracted from the medi-
cal record.
Statistical Analysis
Longitudinal compliance rates were quantified by calculating the pro-
portion of patients who self-reported at least once during each of three differ-
ent timeframes of analysis, respectively: monthly, every 2 weeks, and weekly.
For example, for weekly compliance, the proportion of patients reporting at
least once was measured for week 1 of enrollment, then week 2, week 3, and so
on, and these proportions were then averaged over the observation period.
This analysis was repeated for bimonthly and monthly compliance rates.
A priori threshold criteria for compliance were set based on prior feasi-
bility studies in related contexts6,25,31 to determine if this data collection
approach merited further development. The feasibility threshold for monthly
compliance was specified as 75% (ie, during each month of study enrollment,
at least 75% of participants, on average, completed a self-report), and for
weekly compliance, it was specified as 60%. Expert consensus determined that
these thresholds were reasonable for this study, principally because these
numbers represent compliance rates that conceivably could be improved with
future interventions to support or encourage participation (to be based on
findings in the study about barriers to self-reporting) and would indicate a data
management strategy worth pursuing in future research. Separately, patient-
level compliance was quantified, defined as the proportion of weeks during
which a given patient self-reported at least once.
A multivariate analysis was used to identify patient characteristics asso-
ciated with higher and lower compliance rates. Baseline patient characteristics
were examined in relationship to compliance via a population-averaged logit
model using generalized estimating equations. Patient-level variables of inter-
est included age, race, sex, education level, cancer type, cancer stage, baseline
ECOG performance status, time since enrollment, and total duration of time
in the study. Odds ratios (ORs) were calculated for each covariate. All reported
P values were two sided, and P values  .05 were interpreted as being statisti-
cally significant.
Reasons for noncompliance were elicited from patients at subsequent
logins or clinic visits and were summarized descriptively. In a separate analysis,
compliance in the weeks before death was evaluated for all patients who died
before the trial closure date to assess if proximity to death reduced compli-
ance rates.
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The size of the cohort was determined by the overall clinical trial, which
was powered to measure effectiveness differences between study arms, with an
a priori projected N for this feasibility substudy of 260 patients to provide a




Between September 2006 and November 2010, 286 eligible pa-
tients were enrolled onto this feasibility study, of whom 64% were
women, and 88% were white; median age was 58 years (range, 30 to 85;
Table 1). By design, all patients met the criteria for being Web avid (ie,
familiarity with Internet based on self-reported access to a computer at
home and prior e-mail experience). Patients were observed until the
study closure date of November 21, 2011. Average enrollment dura-
tion was 34 weeks (range, 2 to 214), totaling 9,771 study weeks, and the
median number of visits was 24 (range, two to 272). Less than 8% of
patients (22 of 286) voluntarily withdrew from the study, and 30% of
patients (86 of 286) died during the study period. Overall, 381 patients
were approached to participate (25% refusal rate), with primary rea-
sons for refusal being “do not plan to follow-up here,” “not enough
time,” “not interested in research,” and “enrolled in another study.”
Symptom Self-Reporting
During the 9,771 total study weeks, participants logged into self-
report using STAR a total of 8,690 times (median, 17 logins per
patient), for an average of 0.9 logins per patient per week. Of these
self-reports, 71% were from home (ie, between visits), and 29% were
from clinic.
Figure 1 shows longitudinal compliance rates for the cohort
using the weekly, every 2 week, and every 4 week time unit thresholds,
respectively. Average monthly compliance was 83% (standard devia-
tion, 25%), whereas average weekly compliance was 62% (standard
deviation, 30%), in both cases meeting the prespecified compliance
thresholds for feasibility. These analyses included reporting both from
home and from clinic. Overall, compliance rates were higher during
the initial 16 weeks of enrollment, following which there was a dropoff
before relative stabilization at approximately 24 weeks.
To evaluate patient compliance with reporting exclusively from
home (ie, between visits), the weekly compliance analysis was repeated
including only weeks during which patients did not have a clinic visit
(Fig 2). The between-visit home compliance rates followed a pattern
similar to the overall compliance rates, decreasing until a plateau at
approximately 24 weeks.
To determine the distribution of individual patient-level compli-
ance, rates over the duration of each participant’s enrollment were
tabulated (Appendix Fig A1, online only), finding that more than half
of patients self-reported in  60% of the weeks they were enrolled.
Figure 3 shows compliance rates in the months preceding death
for the 86 patients who died during the study using the monthly
compliance criterion. Patient compliance remained relatively stable
until the last month before death, at which time it declined to 35%.
Self-reported reasons for noncompliance are summarized in Ta-
ble 2. Seventy-three percent of patients said they forgot, were too busy,
or did not feel like self-reporting. Technical and illness-related barriers
to self-reporting were noted by 11%.
Associations of Variables With Compliance
Table 3 summarizes the associations between variables of interest
and weekly self-reporting compliance. Baseline older age, white race,
and higher educational level were significantly associated with com-
pliance, with modest OR differences. Patients were more than 3 as





Female sex 184 64
Race
White 253 88
Black/African American 20 7
Asian/Far East/Indian 12 4
Native American 1  1
Primary cancer site





High school or less 45 16
College 144 51
Professional degree 96 34
Gynecologic includes ovarian, cervical, uterine, and primary peritoneal
cancers.
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Fig 1. Proportion of patients self-reporting symptomatic toxicities over time,
measured using three different compliance definitions: at least one self-report
per week, at least one self-report per 2-week period, or at least one self-report
per month.
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likely to be compliant with self-reporting during their first 12 weeks in
the study than they were after that time (OR, 3.31; P  .001). Patients
with lung and genitourinary cancers were more likely than patients
with breast cancer to be compliant, which may have been related to a
sex effect seen in a separate model, in which men were more likely to be
compliant than women (OR, 1.31; P  .001). Participants with later-
stage cancers were also more likely to be compliant (OR, 1.19;
P  .001). Baseline ECOG performance status scores were not associ-
ated with differences in compliance.
Because this study was initiated in 2006, when Web use and
familiarity with technology was less prevalent than later years of the
study (patients were observed until late 2011), an analysis was con-
ducted to assess if compliance rates differed for patients enrolled in
earlier years of the study versus in later years. No significant difference
was seen in compliance rates based on year of enrollment.
DISCUSSION
This study suggests that long-term between-visit Web-based reporting
of symptomatic toxicities is feasible for patients receiving cancer
chemotherapy. Patients were observed for up to 4 years, with a mean
follow-up of 8.5 months. Compliance rates were higher for longer
timeframes of reporting (ie, monthly v weekly). The principal reasons
given by patients for missing a report were that they forgot or were too
busy. It was much less common for ill health to serve as a barrier (7%
of missing data were attributed by patients to being too ill), and
compliance rates were maintained until shortly before death, corrob-
orating previously published results.25 Similarly, technical difficulties
were rarely a barrier.
Prior work by our group and others has shown high rates of
compliance for patient self-reporting in regulatory clinical trials.21-23
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Fig 2. Proportion of patents self-reporting at least once per week from home
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Fig 3. Proportion of patients self-reporting at least once per month, shown for
each month during the year before death.
Table 2. Primary Reasons Given by Patients for Missing a Self-Report
Reason %
I forgot 42
I was too busy 21
I didn’t feel like it 10
It was inconvenient 9
I was too sick 7
I was feeling well 5
Technical problems 4
I didn’t find it useful 2
Table 3. Multivariate Analysis of Associations of Variables With Patient
Online Reporting Compliance
Variable Adjusted OR P
Age 1.01 .029
White race† 1.38 .001
Higher education‡ 1.20 .028
Breast clinic (reference clinic) — —
Gynecologic clinic 1.07 .437
Lung clinic 1.72  .001
Genitourinary clinic 1.46  .001
Duration on study 1.00 .018
First 3 months of data§ 3.31  .001
Baseline ECOG performance status 0.95 .468
Abbreviations: ECOG, Eastern Cooperative Oncology Group; OR, odds ratio.
P  .05.
†Race was divided into two groups (white or nonwhite) because of a limited
number of nonwhite patients in the study.
‡Education was divided into two groups: having a college degree or higher
versus having less than a college degree.
§The first 3 months of data were compared with all data after that point.
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when patients self-report using tablet computers in waiting rooms—if
staff members approach and remind them to log in.6,24,25 But there has
been limited information about whether patients can be engaged to
report their symptoms from home between visits on a regular basis,
particularly over long periods of time. Information about this context
of PRO use is increasingly important because various stakeholders
consider using PROs for routine remote monitoring of symptoms, for
longitudinal registries, and for use in quality assessment programs.
This study therefore provides essential information for moving this
field forward.
In particular, these findings offer insights toward developing
future data collection strategies to increase compliance rates. Al-
though the compliance rates in this study met the prespecified criteria
for concluding feasibility and for meriting further development, there
were still many patients who did not self-report during any given
month or week. Because the principal reason for missing self-reports
was that patients forgot (whereas impaired functional status or tech-
nical problems were not substantial barriers), better integration of
PROs into regular workflow and improved reminder systems are
likely to boost compliance rates in future work. Approaches that have
been successful in increasing compliance in industry-sponsored clin-
ical trials include reminder telephone calls from a central telephone
bank as well as personalized automated reminder e-mails, telephone
calls, or letters with the name of the patient’s nurse or physician
encouraging participation.21 Because this study was not a part of
regular clinical workflow but rather was an add-on study, it did not
have the feeling of being an expected part of care or clinical operations
either to staff or patients.
Offering patients a menu of interfaces (ie, multiple modes of
questionnaire administration), such as an automated telephone sys-
tem (eg, interactive voice response system), handheld device, and
computer, may also improve accessibility and compliance. Many con-
temporary electronic platforms outside of health care are accessible via
multiple modes (eg, online banking).
Limitations of this study include its conduct at a single urban
tertiary cancer center with a predominantly white, educated patient
population who could read and understand English. By design, only
patients with home Web access and e-mail experience were included
(over the entire duration of this study, 27% of approached patients
were deemed ineligible because they did not have home Internet
access; ie, approximately one in every four patients approached). This
rarified sample may have overestimated broader compliance rates.
Nonetheless, this study provides an initial understanding of challenges
faced when translating PRO approaches from the regulatory context
into routine care settings. This study started in 2006 when electronic
communications were less developed than they are currently. More
patients are now connected electronically (including with their health
providers),38,39 and hence, the applicability of this work may be
greater, and current eligibility and compliance may be superior to
those observed in this study.
Although this study focused on remote self-reporting for the
purposes of symptom monitoring and management, the strategies
used here have broader applications. There is growing interest in use of
PROs for evaluating quality of care as well as in comparative effective-
ness research. In both of these settings, non–highly selected patients
are asked to report their experiences with clinical care and treatment,
and the barriers faced in this study are likely to be experienced there as
well. The risk of nonrandom missing data, particularly from the hard-
est to reach individuals, is a threat in these contexts.
It has also been suggested that severe toxicities or functional
status impairment may hinder self-reporting, but in this study,
ECOG performance status was not associated with compliance,
and patients rarely attributed noncompliance to being too sick.
Nonetheless, compliance rates did decline in the month before
death, suggesting reasons related to disease progression that may
affect willingness or ability to self-report. Future research on bar-
riers and strategies for minimizing missing PRO data in outpatient
nontrial contexts is warranted.
In conclusion, this analysis is intended to provide insights for
further integration of between-visit symptom reporting in routine
care settings, leading to more patient-centered treatment, improved
patient-provider communication, enhanced quality of care, and in-
creased patient satisfaction.
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Fig A1. Histogram of individual patient compliance. Individual compliance is defined for each patient as the number of weeks with at least one report divided by the
total number of weeks enrolled onto the study.
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